Clinical trials: Healthy Volunteers Obesity
Healthy Participants
A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD6234 After Repeat Dose Administration in Participants Who Are Overweight or Obese
A study in healthy male and female participants of non-childbearing and childbearing potential who have overweight or obesity
- Trial name
- NCT06132841
- Testing
- AZD6234
- Where
- 3 sites in United States, Japan
- Volunteers
- 104 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Healthy
Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ZT003 Injection Following Single and Multiple Subcutaneous Administration in Healthy Volunteers/Overweight or Obese Volunteers
This is a Phase 1, randomized, double-blind, placebo-controlled, single-center study designed to evaluate the safety, tolerability, and pharmacokinetics of ZT003 following subcutaneous administration in healthy adult…
- Trial name
- NCT07184502
- Testing
- ZT003 - Part1 (Single ascending dose ), ZT003 - Part 2(Multiple ascending dose )
- Where
- 2 sites in Australia
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Beijing QL Biopharmaceutical Co.,Ltd
Healthy Participants
A Trial to Assess the Relative Bioavailability of Different Subcutaneous Formulations of AZD9550 and AZD6234
This study in healthy volunteers aims to compare blood levels and side effects after administration of different formulations of two test medicines, AZD9550 and AZD6234.
- Trial name
- NCT07911514
- Testing
- AZD9550 solution for injection, AZD6234 solution for injection, Formulation 1 solution for injection
- Where
- United Kingdom
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Overweight or Obesity
A Study of SYH2092 Injection in Healthy Participants
To evaluate the safety and tolerability of SYH2092 Injection in healthy participants
- Trial name
- NCT07776041
- Testing
- SYH2092 Injection
- Where
- Australia
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- CSPC Megalith Biopharmaceutical Co.,Ltd.
Overweight or Obesity
A Phase 1 Study to Evaluate EMP22 PD and EMP16 PK Versus Xenical® in Healthy Volunteers
This Phase I, active-controlled, randomised trial will be conducted in 2 parts. Part I aims to confirm the PD equivalence of EMP22 and Xenical® based on percent fecal fat excretion at steady state.
- Trial name
- NCT06013163
- Testing
- Xenical® vs EMP 22, EMP 22 vs Xenical®, EMP 16 vs Xenical®
- Where
- Sweden
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Empros Pharma AB
Obesity
A Study to Investigate the Safety, Tolerability, Pharmacokinetic/Pharmacodynamic Characteristics and Food Effect of HSG4112 in High Doses
1. Study Objective i) To evaluate the safety, tolerability and pharmacokinetic/pharmacodynamic characteristics of HSG4112 after single and multiple oral administration of high doses in healthy subjects.
- Trial name
- NCT05310032
- Testing
- HSG4112
- Where
- South Korea
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Glaceum
Obese But Otherwise Healthy Participants
A 2-part, Phase 1b Clinical Study Designed to Evaluate the Safety, PK, and Efficacy of CRB-913 in Participants With Obesity
This study will assess the safety of the investigational drug CRB-913 and how it is processed in the body. The study has two parts: Part 1 will measure drug levels in healthy adults after taking CRB-913 tablets, and Part 2 will…
- Trial name
- CANYON-1 (NCT07310901)
- Testing
- CRB-913
- Where
- 15 sites in United States
- Volunteers
- 254 people
- Sponsor
- Corbus Pharmaceuticals Inc.
Healthy Volunteers;, Obese, Otherwise Healthy Volunteers
A Study to Examine the, Safety, Tolerability and Pharmacokinetics Co-Administered Baclofen and Memantine in Obese and Lean, Otherwise Healthy Adults
The purpose of this study is to investigate the safety, tolerability and pharmacokinetics of a predefined dose range of co-administered Baclofen and Memantine in non-obese (Part A) and obese (Part B), otherwise healthy subjects.
- Trial name
- NCT02001584
- Testing
- Baclofen, Memantine
- Where
- United Kingdom
- Sponsor
- Gedeon Richter Plc.
Healthy
A Study Of PF-04620110 As A Modified-Release Formulation In Healthy Overweight Or Obese Subjects
The primary purpose of this trial is to evaluate the safety and tolerability, pharmacokinetics and pharmacodynamics, of multiple oral doses of PF-04620110 as a modified-release formulation.
- Trial name
- NCT01474941
- Where
- Belgium
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Pfizer
Obesity
A Study to Measure the Effects of Using Tradipitant on Nausea and Vomiting After GLP-1R Agonist Use
The goal of this study is to measure the effects of using Tradipitant after GLP-1R agonist use on nausea and vomiting in healthy overweight, class I, or class II obese volunteers.
- Trial name
- NCT06804603
- Testing
- Tradipitant
- Where
- 3 sites in United States
- Volunteers
- 124 people
- Sponsor
- Vanda Pharmaceuticals
Healthy Participants
A Study to Investigate the Effect of AZD6234, AZD9550, and a Combination of AZD9550 and AZD6234 on Pharmacokinetics of Combined Oral Contraceptive Ethinyl Estradiol/Levonorgestrel in Healthy Female Participants Living With Overweight or Obesity
This study will measure the effects of multiple doses of AZD6234, AZD9550 and a combination of AZD9550 and AZD6234 given as injection(s) on pharmacokinetics (PK) of combined oral contraceptive (CoC) ethinyl estradiol…
- Trial name
- NCT07013643
- Testing
- AZD6234, Ethinyl estradiol/Levonorgestrel (EE/LEVO), Acetaminophen (APAP)
- Where
- 2 sites in United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Healthy, Obesity
A Study of LY3971297 in Healthy Participants
The purpose of this study is to measure side effects of LY3971297 injection administered under the skin in healthy participants and obese participants with high blood pressure (BP).
- Conditions
- Healthy, Obesity, Hypertension
- Trial name
- NCT06148272
- Testing
- LY3971297, LY3971297 IV
- Where
- 7 sites in United States, Japan and 1 more
- Volunteers
- 200 people
- Sponsor
- Eli Lilly and Company
Healthy, Overweight
Effects of Pioglitazone on Insulin Sensitivity in Healthy Overweight and Obese Males (MK-0000-170)
The purpose of this study is to evaluate whether 30 mg of pioglitazone administered once daily for up to 28 days to healthy overweight and obese subjects will lead to a significant change in insulin sensitivity, measured in the…
- Conditions
- Healthy, Overweight, Obesity
- Trial name
- NCT01115712
- Testing
- Comparator: Pioglitazone, Comparator: Hyperinsulinemic Euglycemic Clamp
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Overweight or Obesity
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HRS-4729 Injection in Healthy Subjects
The study is being conducted to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of HRS-4729 injection in healthy subjects.
- Trial name
- NCT06762600
- Testing
- HRS-4729 injection, HRS9531 injection, Acetaminophen
- Where
- China
- Volunteers
- 102 people, healthy volunteers welcome
- Sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd.
Overweight, Obesity
A Study of LY3537031 in Overweight, Obese, and Healthy Participants
This is a 4-part study that includes a Part A, Part B, Part C, and Part D. Parts A and D will study the safety and tolerability of the study drug known as LY3537031 in participants who are overweight and obese.
- Trial name
- NCT06606106
- Testing
- LY3537031
- Where
- 5 sites in United States
- Volunteers
- 302 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Obesity
To Investigate the Safety, Tolerability and Pharmacodynamics of GSK2890457 in Healthy Volunteers and Subjects With Type 2 Diabetes
This study is the first administration of GSK2890457 in humans. The study will be conducted in 3 parts: - Part A (conducted at a single investigative site) will determine the safety and tolerability of GSK2890457 alone in healthy…
- Trial name
- NCT01725126
- Testing
- GSK2890457, Metformin, Liraglutide
- Where
- 3 sites in United States
- Volunteers
- 53 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Healthy Volunteers, Overweight
Research Study to Investigate How a Study Medicine (NNC9204- 1177) Affects Blood Levels of Other Medicines in Healthy People
The study looks at how the study medicine (NNC9204-1177) affects other medicines in the body. Participants will get the study medicine and 5 other medicines which have all been approved by the authorities.
- Conditions
- Healthy Volunteers, Overweight, Obesity
- Trial name
- NCT04059367
- Testing
- NNC9204-1177, Cocktail of 5 already approved drugs
- Where
- United States
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Obesity
Safety & Tolerability of a Combination of Antidepressant and Peptic Ulcer Drug in Overweight Healthy Subjects
The hypothesis of this study is that up to 150 mg of sertraline and up to 3 mg of telenzepine will be safe, tolerable, and have the effect of suppressing appetite, when taken in combination daily by mouth by healthy, overweight…
- Trial name
- NCT01155531
- Testing
- Sertraline plus Telenzepine
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Theracos
Overweight or Obesity; Type 2 Diabetes
A Study of Single and Multiple Doses HRS9531 Tablets in Healthy Subjects
The study is being conducted to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple doses of HRS9531tablets in healthy subjects.
- Trial name
- NCT06435676
- Testing
- HRS9531
- Where
- China
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd.
Type 2 Diabetes Mellitus (T2DM), Overweight or Obese
A Study of BGM0504 in Healthy Participants and Participants With Impaired Renal Function
The purpose of this study is to assess how fast BGM0504 gets into the blood stream and how long it takes the body to remove it in participants with impaired kidney function compared to healthy participants.
- Trial name
- NCT06929156
- Testing
- BGM0504
- Where
- China
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- BrightGene Bio-Medical Technology Co., Ltd.